SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior notes due 2031 in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate principal amount of the offering was increas ...

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Cytokinet ...

PresentationMaxwell SkorEquity Analyst All right. Great. I'm Max Skor, a biotech analyst with Morgan Stanley. And before we get started, I'd like to read some quick disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. And with that, I am happy to welcome the Cytokinetics team. With us today is Fady Malik, Head of R&D; Sung Lee, CF ...

Cytokinetics (NasdaqGS:CYTK) FY Conference September 09, 2025 11:30 AM ET Company ParticipantsMaxwell Skor - VP - Biotech Equity ResearchFady Malik - EVP - R&DAndrew Callos - EVP & Chief Commercial OfficerSung Lee - Executive VP & CFOMaxwell SkorAll right, great. I'm Max Skorer, a biotech analyst with Morgan Stanley. Before we get started, I'd like to read some quick disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures ...

核心事件 - Cytokinetics公司股票在9月2日单日暴涨40.4% 受其心血管候选药物aficamten的III期研究积极结果驱动[1] - 公司于8月30日在欧洲心脏病学会大会2025上公布MAPLE-HCM研究的初步结果 结果同步发表于《新英格兰医学杂志》[1] 临床研究设计 - MAPLE-HCM是一项III期随机、双盲、活性对照临床研究 比较aficamten与美托洛尔在症状性梗阻性肥厚型心肌病（oHCM）患者中的效果[3] - 研究纳入175名患者 平均随机分配接受aficamten或美托洛尔单药治疗[4] - 研究针对病情较轻的oHCM患者 入组患者静息时无梗阻且预测峰值摄氧量（pVO2）较高[4] 主要疗效结果 - aficamten在所有临床相关疗效终点上均优于标准治疗药物美托洛尔[5] - 主要终点为治疗24周后pVO2较基线的平均变化 aficamten组增加1.1 mL/kg/min 美托洛尔组下降1.2 mL/kg/min[5] - 组间最小二乘均值差异为2.3 mL/kg/min 具有统计学显著性[6] - aficamten对pVO2的改善效果在所有预设亚组中保持一致[6] 次要疗效结果 - aficamten在六个次要终点中的五个显示优于美托洛尔[9] - 51%的aficamten治疗患者纽约心脏协会（NYHA）心功能分级改善至少一级 美托洛尔组仅为26%[10] - aficamten显著改善静息左心室流出道（LVOT）梯度和Valsalva LVOT梯度[10] - 左心室射血分数（LVEF）仅有适度降低 仅一例患者出现LVEF低于50%[10] 安全性与额外数据 - aficamten心房颤动的年发生率为1.5%[12] - 长期数据与先前报告的安全性特征一致[12] - 新分析显示aficamten较美托洛尔改善心脏结构和功能[12] 监管进展 - aficamten正在美国接受监管审查 FDA设定的目标审批日期为2025年12月26日[13] - FDA将目标审批日期从2025年9月26日延长至12月26日 因要求提交REMS（风险评估与减灾策略）[14] - REMS被FDA确定为新药申请（NDA）的重大修订 导致标准三个月延期[15] - 未要求提交额外临床数据或研究[15] 市场竞争 - 若获批 aficamten将面临百时美施贵宝（BMY）同类首创新药Camzyos（mavacamten）的竞争[16] - Camzyos于2022年获FDA批准用于治疗症状性NYHA II-III级梗阻性HCM成人患者[16] 公司股价表现 - Cytokinetics年初至今股价上涨5.4% 同期行业涨幅为5.1%[2]

Presentation David LebowitzResearch Analyst Thanks everybody for coming to the Citi Biopharma Conference. Next on the docket, we have with us Cytokinetics. They had some interesting news today. I'm sure we'll discuss it. Before we jump into that, if you could all just introduce yourselves and give us kind of the brief history of Cytokinetics, and then we'll jump in. Robert I. BlumCEO, President & Director So good afternoon. Thanks to the folks at Citi for inviting us to the conference today. It's a big ...

Cytokinetics (CYTK) Conference September 02, 2025 02:30 PM ET Company ParticipantsRobert I. Blum - CEO, President & DirectorFady Malik - EVP - R&DSung Lee - Executive VP & CFOIsaac Ciechanover - EVP, Corporate Development and Chief Business OfficerNoneEverybody for coming to the City Bio Pharma Conference. Next on the docket, we have with us Cytokinetics. They had some interesting news today. I'm sure we'll discuss it. Before we jump into that, if you could all just introduce yourselves and give us a kind o ...

With a background as an RN and an MBA, Stephen analyzes healthcare and tech stocks through the lens of investment process design. His work is guided by his proprietary "Dizzy Framework," a system developed to counter common behavioral errors like chasing market noise or rigidly sticking to priors. By focusing on the quality and timing of information, the framework enforces a patient and disciplined approach, translating complex science and market dynamics into truly actionable theses. His influences include ...

百事公司 - 股价上涨5.8% 因激进投资机构Elliott Management持有其40亿美元股份 [1] Cytokinetics公司 - 股价上涨27.2% 因aficamten临床试验显示对梗阻性肥厚型心肌病患者有显著疗效 [1] Constellation Brands公司 - 股价下跌7.3% 因公司下调全年业绩指引 [1] 贝壳公司 - 股价上涨2.1% 绩后获多家机构重申"买入"评级 [1]

Cytokinetics (CYTK) Update / Briefing September 02, 2025 08:30 AM ET Company ParticipantsDiane Weiser - SVP - Corporate AffairsFady Malik - EVP - R&DPablo Garcia-Pavia - CardiologistCarolyn Ho - Medical Director - Cardiovascular Genetics CenterAhmad Masri - Head - Cardiomyopathy SectionDaniel Jacoby - VP - Clinical ResearchAnjali Owens - Cardiovascular FellowRobert I. Blum - CEO, President & DirectorDiane WeiserWelcome, everyone, and thanks for joining. I'm Diane Weiser, SVP, corporate affairs. We're please ...